Crystalys Therapeutics
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
$130MSeries B
Role not disclosedWM
Wellington Management
Activity from announced rounds
Activity in this selectionHealthtech
Wellington Management is an investment manager with a private-investing platform spanning venture capital, growth and private debt, informed by its public-market research.
Its equity strategies include early-stage venture, private biotech, climate growth and late-stage growth. These teams address different development needs, from scientific breakthroughs and medical demand to scaling industrial systems and preparing for public markets.
A Value Creation Team connects portfolio companies with Wellington’s public- and private-market specialists from seed through IPO. The wider platform also provides growth lending, giving some businesses a debt-financing route alongside equity capital.
Sources
- Rounds participated in
- 4
- Confirmed lead rounds
- — 4 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $500M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionRQ Bio
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
$115MSeries A
Role not disclosedCurrent
Provides consumer fintech platform helping everyday Americans improve their financial lives
$80MSeries E
Role not disclosedKorsana Biosciences
Develops therapies for neurodegenerative diseases.
$175MSeries A
Role not disclosed